Company Overview and News

 
Weather is unseasonably sucky for Wesfarmers' BUKI

2018-02-05 theage.com.au
Wesfarmers on Monday revealed a $1 billion write-down of Bunnings UK and Ireland or, as it is known to those required to answer for it internally, the half-rhyme inviting "BUKI".
Upvote Downvote

 
Weather is unseasonably sucky for Wesfarmers' BUKI

2018-02-05 smh.com.au
Wesfarmers on Monday revealed a $1 billion write-down of Bunnings UK and Ireland or, as it is known to those required to answer for it internally, the half-rhyme inviting "BUKI".
Upvote Downvote

 
Punt on Pilbara gold in rich race

2017-11-04 perthnow.com.au
IT’S the biggest punt going in Australia — $1 billion and counting — and Gary Morgan can’t get a bet on.
Upvote Downvote

 
Notice of General Meeting & Corporate Update

2017-04-28 londonstockexchange
Keras Resources plc, the AIM listed mineral resource company, announces that a circular and Notice of General Meeting will be posted to shareholders on 2 May 2017 ("the Circular") relating to the proposed acquisition by Pharmanet Group Limited ("Pharmanet") of 100% of the issued share capital of the Company's wholly owned subsidiary Keras (Gold) Australia Pty Ltd ("Keras Australia") as previously announced on 21 March 2017 (the "Transaction").
Upvote Downvote

 
Initial High Grade Resource at Copenhagen Deposit

2017-02-14 londonstockexchange
Keras Resources plc is pleased to announce an initial Inferred Mineral Resource at the Copenhagen Deposit, which along with the Company's flagship Klondyke Gold Project ('Klondyke'), comprises the Warrawoona Gold Project ('Warrawoona') in the East Pilbara Gold Belt of the Pilbara Goldfield of Western Australia.
Upvote Downvote

 
Final Results

2016-12-20 londonstockexchange
Keras Resources plc, the Australian gold mining company, is pleased to announce its final results for the year ended 30 September 2016.
Upvote Downvote

 
Completion of Acquisition of Klondyke Gold Project

2016-10-05 londonstockexchange
Keras Resources plc, the Australian gold mining company, is pleased to announce that, further to the announcement of 12 September 2016, it has completed the acquisition of the Klondyke Gold Project ('Klondyke' or 'the Project') and the Haoma Mining NL ("HML") Right to Mine and Option to Purchase Agreement in the Pilbara region of Western Australia.  These transactions are part of the Company's strategy to become a significant gold producer in Western Australia.
Upvote Downvote

 
Acquisition of Klondyke Gold Project

2016-09-12 londonstockexchange
Click on or paste the following link into your web browser to view the associated PDF document:
Upvote Downvote

 
Gary Morgan strikes gold at last with Haoma

2016-05-02 smh.com.au
Haoma Mining, the alchemist heavily backed by pollster Gary Morgan, was a big bolter on Monday after the company reported more success with the gold extraction technique it licenses from another Morgan company, Elazac. 
Upvote Downvote

 
 
Haoma Mining NL to reveal results of test work

2016-04-29 proactiveinvestors.com.au
Haoma Mining NL (ASX:HAO) is engaged in gold mining, mineral exploration and mining development, with operations in Australia. Currently, the company is focused on the Bamboo Creek and Mt Webber Projects in Western Australia.
Upvote Downvote

 
Trading Halt

2016-04-29 asx.com.au
Upvote Downvote

 

Related Articles

LPCN: Lipocine Inc Analysis and Research Report

23h - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...